Literature DB >> 29980573

Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells.

Hyun Don Yun1, Martin Felices1, Daniel A Vallera2, Peter Hinderlie1, Sarah Cooley1, Michel Arock3,4, Jason Gotlib5, Celalettin Ustun1, Jeffrey S Miller1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29980573      PMCID： PMC6039654          DOI： 10.1182/bloodadvances.2018018176

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  17 in total

1.  Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia.

Authors:  I Alvarez-Twose; P Martínez-Barranco; J Gotlib; A García-Montero; J M Morgado; M Jara-Acevedo; J D Merker; F J Peñalver; A Matito; Y Hou; L Sánchez-Muñoz; A Mayado; M Mollejo; L Escribano; A Orfao
Journal:  Leukemia       Date:  2016-02-15       Impact factor: 11.528

2.  Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.

Authors:  Celalettin Ustun; Andreas Reiter; Bart L Scott; Ryotaro Nakamura; Gandhi Damaj; Sebastian Kreil; Ryan Shanley; William J Hogan; Miguel-Angel Perales; Tsiporah Shore; Herrad Baurmann; Robert Stuart; Bernd Gruhn; Michael Doubek; Jack W Hsu; Eleni Tholouli; Tanja Gromke; Lucy A Godley; Livio Pagano; Andrew Gilman; Eva Maria Wagner; Tor Shwayder; Martin Bornhäuser; Esperanza B Papadopoulos; Alexandra Böhm; Gregory Vercellotti; Maria Teresa Van Lint; Christoph Schmid; Werner Rabitsch; Vinod Pullarkat; Faezeh Legrand; Ibrahim Yakoub-Agha; Wael Saber; John Barrett; Olivier Hermine; Hans Hagglund; Wolfgang R Sperr; Uday Popat; Edwin P Alyea; Steven Devine; H Joachim Deeg; Daniel Weisdorf; Cem Akin; Peter Valent
Journal:  J Clin Oncol       Date:  2014-08-25       Impact factor: 44.544

3.  Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications.

Authors:  L Escribano; A Orfao; B Díaz-Agustin; J Villarrubia; C Cerveró; A López; M A Marcos; C Bellas; S Fernández-Cañadas; M Cuevas; A Sánchez; J L Velasco; J L Navarro; J F Miguel
Journal:  Blood       Date:  1998-04-15       Impact factor: 22.113

4.  Effects of the CD33-targeted drug gemtuzumab ozogamicin (Mylotarg) on growth and mediator secretion in human mast cells and blood basophils.

Authors:  Maria-Theresa Krauth; Alexandra Böhm; Hermine Agis; Karoline Sonneck; Puchit Samorapoompichit; Stefan Florian; Karl Sotlar; Peter Valent
Journal:  Exp Hematol       Date:  2007-01       Impact factor: 3.084

Review 5.  Diagnostic criteria and classification of mastocytosis: a consensus proposal.

Authors:  P Valent; H P Horny; L Escribano; B J Longley; C Y Li; L B Schwartz; G Marone; R Nuñez; C Akin; K Sotlar; W R Sperr; K Wolff; R D Brunning; R M Parwaresch; K F Austen; K Lennert; D D Metcalfe; J W Vardiman; J M Bennett
Journal:  Leuk Res       Date:  2001-07       Impact factor: 3.156

6.  GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity.

Authors:  Frank Cichocki; Bahram Valamehr; Ryan Bjordahl; Bin Zhang; Betsy Rezner; Paul Rogers; Svetlana Gaidarova; Stacey Moreno; Katie Tuininga; Phillip Dougherty; Valarie McCullar; Peter Howard; Dhifaf Sarhan; Emily Taras; Heinrich Schlums; Stewart Abbot; Daniel Shoemaker; Yenan T Bryceson; Bruce R Blazar; Scott Wolchko; Sarah Cooley; Jeffrey S Miller
Journal:  Cancer Res       Date:  2017-08-08       Impact factor: 12.701

Review 7.  Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice.

Authors:  Celalettin Ustun; Michel Arock; Hanneke C Kluin-Nelemans; Andreas Reiter; Wolfgang R Sperr; Tracy George; Hans-Peter Horny; Karin Hartmann; Karl Sotlar; Gandhi Damaj; Olivier Hermine; Srdan Verstovsek; Dean D Metcalfe; Jason Gotlib; Cem Akin; Peter Valent
Journal:  Haematologica       Date:  2016-10       Impact factor: 9.941

8.  Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V.

Authors:  Celalettin Ustun; Christopher L Corless; Natasha Savage; Warren Fiskus; Elizabeth Manaloor; Michael C Heinrich; Grant Lewis; Preetha Ramalingam; Ilana Kepten; Anand Jillella; Kapil Bhalla
Journal:  Leuk Res       Date:  2008-11-04       Impact factor: 3.156

9.  Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells.

Authors:  Daniel A Vallera; Bin Zhang; Michelle K Gleason; Seunguk Oh; Louis M Weiner; Dan S Kaufman; Valarie McCullar; Jeffrey S Miller; Michael R Verneris
Journal:  Cancer Biother Radiopharm       Date:  2013-04-23       Impact factor: 3.099

10.  Comparative analysis of NK cell subset distribution in normal and lymphoproliferative disease of granular lymphocyte conditions.

Authors:  Véronique Pascal; Nicolas Schleinitz; Corinne Brunet; Sophie Ravet; Elodie Bonnet; Xavier Lafarge; Mhammed Touinssi; Denis Reviron; Jean Francois Viallard; Jean Francois Moreau; Julie Déchanet-Merville; Patrick Blanco; Jean Robert Harlé; José Sampol; Eric Vivier; Françoise Dignat-George; Pascale Paul
Journal:  Eur J Immunol       Date:  2004-10       Impact factor: 5.532
View more
  10 in total

1.  Dinaciclib enhances natural killer cell cytotoxicity against acute myelogenous leukemia.

Authors:  Hyun Don Yun; Dawn K Schirm; Martin Felices; Jeffrey S Miller; Craig E Eckfeldt
Journal:  Blood Adv       Date:  2019-08-27

2.  Potent Cytolytic Activity and Specific IL15 Delivery in a Second-Generation Trispecific Killer Engager.

Authors:  Martin Felices; Todd R Lenvik; Behiye Kodal; Alexander J Lenvik; Peter Hinderlie; Laura E Bendzick; Dawn K Schirm; Michael F Kaminski; Ron T McElmurry; Melissa A Geller; Craig E Eckfeldt; Daniel A Vallera; Jeffrey S Miller
Journal:  Cancer Immunol Res       Date:  2020-07-13       Impact factor: 11.151

3.  Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL.

Authors:  Martin Felices; Behiye Kodal; Peter Hinderlie; Michael F Kaminski; Sarah Cooley; Daniel J Weisdorf; Daniel A Vallera; Jeffrey S Miller; Veronika Bachanova
Journal:  Blood Adv       Date:  2019-03-26

Review 4.  Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry.

Authors:  Fabien Thoreau; Vijay Chudasama
Journal:  RSC Chem Biol       Date:  2021-10-22

Review 5.  An Historical Overview: The Discovery of How NK Cells Can Kill Enemies, Recruit Defense Troops, and More.

Authors:  Massimo Vitale; Claudia Cantoni; Mariella Della Chiesa; Guido Ferlazzo; Simona Carlomagno; Daniela Pende; Michela Falco; Annamaria Pessino; Letizia Muccio; Andrea De Maria; Emanuela Marcenaro; Lorenzo Moretta; Simona Sivori
Journal:  Front Immunol       Date:  2019-06-19       Impact factor: 7.561

Review 6.  Challenges and Recent Advances in NK Cell-Targeted Immunotherapies in Solid Tumors.

Authors:  Guangyu Lian; Thomas Shiu-Kwong Mak; Xueqing Yu; Hui-Yao Lan
Journal:  Int J Mol Sci       Date:  2021-12-23       Impact factor: 5.923

Review 7.  Emerging new therapeutic antibody derivatives for cancer treatment.

Authors:  Shijie Jin; Yanping Sun; Xiao Liang; Xinyu Gu; Jiangtao Ning; Yingchun Xu; Shuqing Chen; Liqiang Pan
Journal:  Signal Transduct Target Ther       Date:  2022-02-07

Review 8.  Bi-specific and Tri-specific NK Cell Engagers: The New Avenue of Targeted NK Cell Immunotherapy.

Authors:  Shee Kwan Phung; Jeffrey S Miller; Martin Felices
Journal:  Mol Diagn Ther       Date:  2021-07-29       Impact factor: 4.074

Review 9.  Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs.

Authors:  Cristina Capuano; Chiara Pighi; Simone Battella; Davide De Federicis; Ricciarda Galandrini; Gabriella Palmieri
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639

Review 10.  Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?

Authors:  Aviad Ben-Shmuel; Guy Biber; Mira Barda-Saad
Journal:  Front Immunol       Date:  2020-02-21       Impact factor: 7.561
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.